1. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis
- Author
-
Miyata, Koichi, Bainto, Emelia V, Sun, Xiaoying, Jain, Sonia, Dummer, Kirsten B, Burns, Jane C, and Tremoulet, Adriana H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Rare Diseases ,Clinical Trials and Supportive Activities ,Clinical Research ,Child ,Humans ,Infant ,Mucocutaneous Lymph Node Syndrome ,Infliximab ,Immunoglobulins ,Intravenous ,Coronary Vessels ,Coronary Aneurysm ,Retrospective Studies ,Coronary Artery Disease ,Paediatrics ,Cardiology ,Rheumatology ,Paediatrics and Reproductive Medicine ,Public Health and Health Services ,Pediatrics ,Clinical sciences - Abstract
ObjectiveChildren with Kawasaki disease (KD) and an initial echocardiogram that demonstrates coronary artery aneurysms (CAAs, Z score ≥2.5) are at high risk for severe cardiovascular complications. We sought to determine if primary adjunctive infliximab treatment at a dose of either 5 or 10 mg/kg, compared with intravenous immunoglobulin (IVIG) alone, is associated with a greater likelihood of CAA regression in patients with KD with CAA at the time of diagnosis.Design and settingSingle-centre observational study.PatientsChildren with acute KD and Z score ≥2.5 at baseline.InterventionsPrimary adjunctive infliximab (5 or 10 mg/kg) within 48 hours of initiating IVIG 2 g/kg.Main outcome measuresIncidence of CAA regression to Zmax
- Published
- 2023